A61P23/02

NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES

The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.

Method and compounds for treating peripheral neuropathy

A medicament set adapted to regulate multiple receptors simultaneously in patients experiencing diabetic peripheral neuropathy pain, the medicament set comprising: at least three distinct and separate medicaments for treating diabetic peripheral neuropathy pain, the at least three medicaments being a first medicament for treating peripheral neuropathy pain, being formulated for clinical administration as a locally injectable medicament using an injection device, and comprising polylactic glycolic acid (PLGA) micro-particles being loaded with a sodium channel blocker and local anesthetic drug, a second medicament for treating peripheral neuropathy pain, being formulated for clinical administration as a locally injectable medicament using an injection device, and comprising PLGA micro-particles being loaded with a sodium channel blocker and anti-convulsant drug, and a third medicament for treating peripheral neuropathy pain, being formulated for clinical administration as a locally injectable medicament using an injection device, and comprising PLGA micro-particles being loaded with an anti-inflammatory drug.

Method and compounds for treating peripheral neuropathy

A medicament set adapted to regulate multiple receptors simultaneously in patients experiencing diabetic peripheral neuropathy pain, the medicament set comprising: at least three distinct and separate medicaments for treating diabetic peripheral neuropathy pain, the at least three medicaments being a first medicament for treating peripheral neuropathy pain, being formulated for clinical administration as a locally injectable medicament using an injection device, and comprising polylactic glycolic acid (PLGA) micro-particles being loaded with a sodium channel blocker and local anesthetic drug, a second medicament for treating peripheral neuropathy pain, being formulated for clinical administration as a locally injectable medicament using an injection device, and comprising PLGA micro-particles being loaded with a sodium channel blocker and anti-convulsant drug, and a third medicament for treating peripheral neuropathy pain, being formulated for clinical administration as a locally injectable medicament using an injection device, and comprising PLGA micro-particles being loaded with an anti-inflammatory drug.

BIOACTIVE IMPLANTS FOR DRUG DELIVERY

The invention provides a device comprising: at least one biocompatible polymer, and an eutectic composition comprising a first agent and an agent capable of forming a eutectic composition with the first agent; or one or more fatty acids; or one or more fatty alcohols; or one or more fatty amines or combinations thereof. The device can be administered to a subject in need thereof an effective amount of one or more active agents. The at least one biocompatible polymer may be selected from the group comprising poly ethylene-vinyl-acetate, vinyl acetate, silicone, polycaprolactone, polylacticco-glycolic acid, polylactic acid or polyglycolic acid.

BIOACTIVE IMPLANTS FOR DRUG DELIVERY

The invention provides a device comprising: at least one biocompatible polymer, and an eutectic composition comprising a first agent and an agent capable of forming a eutectic composition with the first agent; or one or more fatty acids; or one or more fatty alcohols; or one or more fatty amines or combinations thereof. The device can be administered to a subject in need thereof an effective amount of one or more active agents. The at least one biocompatible polymer may be selected from the group comprising poly ethylene-vinyl-acetate, vinyl acetate, silicone, polycaprolactone, polylacticco-glycolic acid, polylactic acid or polyglycolic acid.

Intravesical drug delivery devices

An implantable medical device is provided for controlled drug delivery within the bladder, or other body vesicle. The device may include at least one drug reservoir component comprising a drug; and a vesicle retention frame which comprises an elastic wire having a first end, an opposing second end, and an intermediate region therebetween, wherein the drug reservoir component is attached to the intermediate region of the vesicle retention frame. The retention frame prevents accidental voiding of the device from the bladder, and it preferably has a spring constant selected for the device to effectively stay in the bladder during urination while minimizing the irritation of the bladder.

SUSTAINED RELEASE OF FORMULATIONS OF LOCAL ANESTHETICS

Described herein are sustained release formulations of polymer-coated local anesthetic agents, and methods for using the same to relieve or manage pain, including postsurgical pain.

SUSTAINED RELEASE OF FORMULATIONS OF LOCAL ANESTHETICS

Described herein are sustained release formulations of polymer-coated local anesthetic agents, and methods for using the same to relieve or manage pain, including postsurgical pain.

SPRAYABLE LIQUID LIDOCAINE SOLUTION
20220347132 · 2022-11-03 ·

The invention relates to a sprayable liquid solution for the local delivery of lidocaine to the epidermis (skin), gingiva, oral mucosa or mucosal lining of the pharynx, and to a method of providing local anesthesia by administering this composition. The solution comprises at least 40% w/w lidocaine, or about 2% to about 50% w/w/ lidocaine.

SPRAYABLE LIQUID LIDOCAINE SOLUTION
20220347132 · 2022-11-03 ·

The invention relates to a sprayable liquid solution for the local delivery of lidocaine to the epidermis (skin), gingiva, oral mucosa or mucosal lining of the pharynx, and to a method of providing local anesthesia by administering this composition. The solution comprises at least 40% w/w lidocaine, or about 2% to about 50% w/w/ lidocaine.